2 The technology

2 The technology

2.1 Ocriplasmin (Jetrea, ThromboGenics [known as Oxurion from September 2018]) is a truncated form of human plasmin, manufactured using recombinant DNA technology. It is 'indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole (MH) of diameter less than or equal to 400 microns'. It is administered by intravitreal injection at a dose of 0.125 mg. Repeated injections into the same eye are not recommended.

2.2 The summary of product characteristics lists the following adverse reactions for ocriplasmin: vitreous floaters, eye pain, photopsia, and conjunctival haemorrhage resulting from the injection procedure. Most of these reactions were non‑serious, mild in intensity and resolved within 2 to 3 weeks. For full details of adverse reactions and contraindications, see the summary of product characteristics.

2.3 The cost of an ocriplasmin injection is £2500 (excluding VAT, ocriplasmin concentrate 0.5 mg in 0.2 ml solution; MIMS, July 2013; from September 2018, this was replaced with ready-diluted 0.375 mg/0.3 ml solution). Because repeat injections are not recommended, this is the cost for a full course of treatment. Costs may vary in different settings because of negotiated procurement discounts.

  • National Institute for Health and Care Excellence (NICE)